poisar

Stocks · News reference

Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate

Benzinga Newsdesk

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 5.13 percent. This is unchanged from the same period last year. The company

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RLAY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option

    Elevar Therapeutics announced FDA approval of Lyrfigtu (lirafugratinib) for treating cholangiocarcinoma patients with FGFR2 fusion or rearrangement. The drug demonstrated a 46% objective response rate and 11.8-month median duration of response in the Phase 1/2 ReFocus trial. Lyrfigtu is expected to be available in the U.S. by Q4 2026 and represents a second-line treatment option for this rare bile duct cancer.

    RLAY
  2. Na

    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

    Relay Therapeutics announced that management will participate in fireside chats at the Wells Fargo Healthcare Conference on September 8, 2026 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The clinical-stage precision medicine company is developing therapies for cancer and genetic diseases, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer.

    RLAY